New drug cocktail aims to fight tough esophageal cancer

NCT ID NCT07554456

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests a new combination of drugs (BL-B01D1 plus tislelizumab, with or without chemotherapy) as a first treatment for people with advanced esophageal cancer that cannot be removed by surgery. About 90 participants will be randomly assigned to receive either the new combo or standard chemotherapy plus immunotherapy. The main goal is to see if the new combo helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a targeted drug) combined with tislelizumab (an immunotherapy), with or without 5-fluorouracil (chemotherapy)
What this could lead to: If it works, this could offer a more effective first-line treatment for advanced esophageal cancer, potentially extending survival.
What could go wrong: This is an early-to-mid-stage trial with only 90 participants. The new drug combo may not work better than standard chemo, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.